SCYNEXIS is a clinical-stage biotechnology company developing differentiated therapies for severe rare diseases, led by SCY-770 for autosomal dominant polycystic kidney disease (ADPKD) and SCY-247 for the treatment and prevention of serious fungal infections, addressing significant unmet needs for patients with limited treatment options.
SCYNEXIS is a clinical-stage biotechnology company developing differentiated therapies for severe rare diseases, led by SCY-770 for autosomal dominant polycystic kidney disease (ADPKD) and SCY-247 for the treatment and prevention of serious fungal infections, addressing significant unmet needs for patients with limited treatment options.
Our strategy is built on advancing programs with validated mechanisms, well-understood regulatory pathways, and clear potential to improve patient outcomes. Following the successful development and FDA approval of ibrexafungerp (BREXAFEMME®), now licensed to GSK, we are focused on developing innovative therapies for patients facing serious and underserved diseases.
Our pipeline targets diseases where patients continue to face limited treatment options, including autosomal dominant polycystic kidney disease (ADPKD) and invasive fungal infections, where significant unmet medical need remains.
RARE KIDNEY DISEASE
A progressive inherited disease in which cyst growth drives declining kidney function, affecting approximately 140,000 diagnosed patients in the United States. SCYNEXIS is developing SCY-770, a first-in-class direct AMPK activator designed to address the metabolic biology underlying cyst formation.
INFECTIOUS DISEASE
Life-threatening fungal infections continue to present significant treatment challenges as resistance to existing therapies increases. SCYNEXIS is advancing next-generation antifungals with a differentiated mechanism and both oral and intravenous formulations, designed to expand treatment options for the treatment and prevention of serious fungal infections.
Our portfolio includes SCY-770, a Phase 2 ready program targeting the underlying biology of autosomal dominant polycystic kidney disease (ADPKD), and SCY-247, a next-generation antifungal designed to address resistant fungal pathogens.
Complementary to these programs are additional antifungals in our preclinical portfolio; ibrexafungerp, an FDA-approved medicine developed by SCYNEXIS and now partnered with GSK; and the potential for SCY-770 to be developed for multiple other indications.
Clinical Development
Rare Kidney Disease (ADPKD)
A first-in-class direct AMPK activator developed to address the metabolic biology underlying cyst growth in autosomal dominant polycystic kidney disease.
Clinical Development
Next-Generation Antifungal Therapy
A second-generation fungerp in development for oral and intravenous treatment and prevention of serious and difficult-to-treat fungal infections.
Preclinical Research
Expanding the Antifungal Platform
Structurally distinct antifungal compounds advancing the next generation of the fungerp platform.
Approved & Licensed
Approved & Partnered Therapy
The first approved medicine from the Fungerp platform, demonstrating SCYNEXIS’ ability to advance innovative therapies through regulatory approval. GSK holds rights in most major markets, with an anticipated product relaunch expected to further demonstrate the long-term commercial value of the Fungerp platform.
Follow SCYNEXIS developments across clinical programs, scientific research, corporate milestones, and investor news.